Abstract
The combination of three or more antiretroviral drugs is referred to as highly active antiretroviral therapy (HAART) and constitutes the standard of care for HIV-1 patients in industrialized nations. Although HAART is usually effective in reducing viral load and re-constituting CD4 counts, latent virus reservoirs persist, and as many as 60 years therapy [1, 2] may be required to eradicate the virus. Meanwhile, patients are likely to experience drug related toxicity and may have to change therapy due to the emergence of drug resistant strains. For these reasons, the search for different therapeutic approaches continues. A new concept of antiviral / cytostatic (“virostatics”) drugs has been proposed within the context of HAART to restrict virus target populations (CD4+ T lymphocytes), target viral reservoirs, and possibly restore immune functions, by reducing excess immune activation, a fundamental component of HIV / AIDS pathogenesis. These virostatics include drugs such as hydroxyurea, mycophenolic acid, leflunomide and rapamycin, which are currently used for other therapeutic indications; and other expe rimental drugs, which are not for human use. They utilize multiple novel mechanisms of action to impede HIV by targeting host cellular proteins that are not susceptible to mutation. Therefore, their resistance profile appears to be quite favorable. Since many of these drugs act by inhibiting the synthesis of deoxynucleotides, essential for HIV reverse transcription, they favor the incorporation of nucleoside analogues into viral DNA, thus synergizing with the antiviral activity of currently used nucleoside reverse transcriptase inhibitors (NRTI). The rationale for the use of virostatics in HIV / AIDS, their mechanism of action, and ongoing preclinical and clinical research will be reviewed.
Keywords: cytostatic, virostatic, hydroxyurea, mycophenolic acid, leflunomide, rapamycin, chronic immune activation
Current Pharmaceutical Design
Title: “Virostatics” as a Potential New Class of HIV Drugs
Volume: 10 Issue: 32
Author(s): L. M. Kelly, J. Lisziewicz and F. Lori
Affiliation:
Keywords: cytostatic, virostatic, hydroxyurea, mycophenolic acid, leflunomide, rapamycin, chronic immune activation
Abstract: The combination of three or more antiretroviral drugs is referred to as highly active antiretroviral therapy (HAART) and constitutes the standard of care for HIV-1 patients in industrialized nations. Although HAART is usually effective in reducing viral load and re-constituting CD4 counts, latent virus reservoirs persist, and as many as 60 years therapy [1, 2] may be required to eradicate the virus. Meanwhile, patients are likely to experience drug related toxicity and may have to change therapy due to the emergence of drug resistant strains. For these reasons, the search for different therapeutic approaches continues. A new concept of antiviral / cytostatic (“virostatics”) drugs has been proposed within the context of HAART to restrict virus target populations (CD4+ T lymphocytes), target viral reservoirs, and possibly restore immune functions, by reducing excess immune activation, a fundamental component of HIV / AIDS pathogenesis. These virostatics include drugs such as hydroxyurea, mycophenolic acid, leflunomide and rapamycin, which are currently used for other therapeutic indications; and other expe rimental drugs, which are not for human use. They utilize multiple novel mechanisms of action to impede HIV by targeting host cellular proteins that are not susceptible to mutation. Therefore, their resistance profile appears to be quite favorable. Since many of these drugs act by inhibiting the synthesis of deoxynucleotides, essential for HIV reverse transcription, they favor the incorporation of nucleoside analogues into viral DNA, thus synergizing with the antiviral activity of currently used nucleoside reverse transcriptase inhibitors (NRTI). The rationale for the use of virostatics in HIV / AIDS, their mechanism of action, and ongoing preclinical and clinical research will be reviewed.
Export Options
About this article
Cite this article as:
Kelly M. L., Lisziewicz J. and Lori F., “Virostatics” as a Potential New Class of HIV Drugs, Current Pharmaceutical Design 2004; 10 (32) . https://dx.doi.org/10.2174/1381612043382495
DOI https://dx.doi.org/10.2174/1381612043382495 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medullary Thyroid Cancer: A Promising Model for Targeted Therapy
Current Molecular Medicine The Critical Role of Insulin-Like Growth Factor-1 Isoforms in the Physiopathology of Skeletal Muscle
Current Genomics Meet Our Editorial Board Member
Current Proteomics Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets Targeting MDM2 and MDMX in Retinoblastoma
Current Cancer Drug Targets Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases
Current Medicinal Chemistry Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?
Current Alzheimer Research NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry MicroRNAs: Modulators of Cell Identity, and their Applications in Tissue Engineering
MicroRNA Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma
Current Signal Transduction Therapy Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Machine Learning for Childhood Acute Lymphoblastic Leukaemia Gene Expression Data Analysis: A Review
Current Bioinformatics Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets The Role Oxidative Stress in the Pathogenesis of Eye Diseases: Currnt Status and a Dual Role of Physical Activity
Mini-Reviews in Medicinal Chemistry